WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

WuXi XDC Cayman Inc

WuXi XDC is a leading CRDMO focused on the global ADC and broader bioconjugate market and is dedicated to providing integrated services from concept development to commercialization. All services are provided from proximately located, state-of-the-art laboratories and manufacturing facilities, providing high efficiency and significant reduction of development timeline and costs. Our community of over 1000 skilled employees work across a global network to provide an open-access platform with the most comprehensive capabilities and technologies.  WuXi XDC enables its biopharmaceutical partners to innovate, accelerate, and transform the development of the bioconjugate industry, to the benefit of patients worldwide.

msh id	COM:WUXIXDC
symbol	2.27K
name	WuXi XDC Cayman Inc
homepage url	https://wuxixdc.com
country	CN
sector	Healthcare
industry	Medical - Diagnostics & Research
market	STOCKS
employee count	1.18K
crunchbase url	-
linkedin url	-
founders	-

market cap	2.68B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	9.8
growth score 28	11.79
growth score 90	11.73
growth score 365	10.67

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	2.35
growth cost of revenue	2.69
growth depreciation and amortization	0.62
growth ebitda	1.82
growth ebitda ratio	-0.12
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.77
growth gross profit	1.3
growth gross profit ratio	-0.28

2268

COM:WUXIXDC

WuxiXDC

Last Close

26.00

22/11 03:59

Market Cap

19.17B

Beta: -

Volume Today

852K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	111.32M
cost of revenue	111.32M
depreciation and amortization	4.26M
ebitda	37.72M
ebitda ratio	0.28
eps	0.02
eps diluted	0.02
operating expenses	10.51M
operating income	33.46M
operating income ratio	0.24

accounts receivables	-
capital expenditure	-53.57M
cash at beginning of period	3.64M
cash at end of period	46.3M
inventory	8.7M
working capital ttm	415.24M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-